Men who had three or more metabolic syndrome components had a 54% greater odds of prostate cancer diagnosis, 56% greater odds of clinically significant PCa and 56% greater odds of intermediate- or high-grade PCa compared with men with no components of metabolic syndrome, data indicated. The findings were published in the journal European Urology.

Related Summaries